Drugs / ARVAC CG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05656508 | Apr → Sep 2022 | — | Laboratorio Pablo Cassará S.R.L. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARVAC CG | “A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called ARVAC CG was selected for a first in human clinical trial.” PMID 37507392 ↗ Jul 2023 |
| Modality | Vaccine | “recombinant protein vaccine against SARS-CoV-2” NCT05656508 ↗ |
| Route | Intramuscular | “Administration route: Intramuscular (IM) injection” NCT05656508 ↗ |